Medicare to Negotiate Lower Prices for Weight-Loss Drugs

That would slow the growth of the government’s spending on obesity drugs even as more people on Medicare started using them.New prices for the 10 drugs in the first round of price negotiations were announced last summer. Those prices will go into effect next year.Drugmakers were relieved that those cuts were not deeper. They have sued, unsuccessfully, to block the price negotiation program.Drugs Selected for Medicare’s Second Round of Price NegotiationsPrices will go into effect in 2027.1. Ozempic, Rybelsus and Wegovy, for diabetes and obesity2. Trelegy Ellipta, for lung conditions3. Xtandi, for prostate cancer4. Pomalyst, for blood cancer5. Ibrance, for breast cancer6. Ofev, for lung conditions7. Linzess, for gastrointestinal conditions8. Calquence, for blood cancers9. Austedo and Austedo XR, for neurological diseases10. Breo Ellipta, for lung conditions11. Tradjenta, for diabetes12. Xifaxan, for liver and gastrointestinal problems13. Vraylar, for depression14. Janumet and Janumet XR, for diabetes15. Otezla, for inflammatory conditions